January 3, 2005 If the January indicators have any validity, biotech and the stock market in general made life hard on themselves on Monday, kicking the month off with a loss. The Centient Biotech 200 lost 32.08 points to 3546.19, a decline of .9%, a slightly smaller drop than the market as a whole. We discuss ArtheroGenics, which stretched out a Phase III trial on its lead drug, SuperGen, which pulled an FDA application, and Alnylam, which bucked the trend by gathering in some new cash...
